Hologic, Inc.  Notes to Consolidated Financial Statements (continued) (In thousands, except per share data) Company’s consolidated financial statements from the date of acquisition as part of its other business segment.
The Company has concluded that the acquisition of AEG does not represent a material business combination and therefore no pro forma financial information has been provided herein.
AEG specializes in the manufacture of photoconductor materials for use in a variety of electro photographic applications including for the coating of the Company’s digital detectors.
The acquisition of AEG allows the Company to have control over a critical step in its detector manufacturing process – to efficiently manage its supply chain and improve manufacturing margins.
The combination of the companies should also facilitate further manufacturing efficiencies and accelerate research and development of new detector products.
AEG was a privately held group of companies headquartered in Warstein, Germany, with manufacturing operations in Germany, China and the United States.
The aggregate purchase price for AEG was approximately $31,300 (subject to adjustment) consisting of EUR $24,100 in cash and 110 shares of Hologic Common Stock valued at $5,300, and approximately $1,900 for acquisition related fees and expenses.
The Company determined the fair value of the shares issued in connection with the acquisition in accordance with EITF Issue No.99-12, Determination of the Measurement Date for the Market Price of Acquirer Securities Issued in a Purchase Business Combination.
These 110 shares are subject to contingent put options pursuant to which the holders have the option to resell the shares to the Company during a period of one year following the completion of the acquisition if the closing price of the Company’s stock falls and remains below a threshold price.
The repurchase price would be the closing price of the Company’s common stock on the date of exercise.
The Company’s maximum aggregate obligation under these put options would be approximately $4,100 if the put option were exercised for all the shares covered by those options and the closing price of our common stock on the date of exercise equaled the maximum threshold price permitting the exercise of the option.
No shares were subject to the put option as of September 30, 2006 as the Company’s stock price was in excess of the minimum value.
The acquisition also provides for a one-year earn out of EUR 1,700 (approximately $2,000 USD) which will be payable in cash if AEG calendar year 2006 earnings, as defined, exceeds a pre-determined amount.
The Company has considered the provision of EITF Issue No.95-8, Accounting for Contingent Consideration Paid to the Shareholders of and Acquired Enterprise in a Purchase Business Combination, and concluded that this contingent consideration represents additional purchase price.
As a result, goodwill will be increased by the amount of the additional consideration, if any, when it becomes due and payable.
The components and allocation of the purchase price, consists of the following approximate amounts:
## Table 0 ##
The purchase price allocation above has been revised from that included in the Company’s Form 10-Q for the period ended June 24, 2006, to decrease the net tangible asset acquired and increased the deferred income tax liability with a corresponding increase to goodwill for both.
The decrease to the net tangible assets primarily
Operating income for osteoporosis assessment increased primarily due to increased revenues and, to a much lesser extent, a reduction in operating expenses.
Our gross margin in this business segment was 44% in fiscal 2005 compared to 43% in fiscal 2004.
The increase in osteoporosis assessment gross margins was primarily attributable to the increase in revenues and related improved absorption of manufacturing costs.
The reduction in operating expenses of $337,000 was primarily attributable to reduced commissions expense, primarily related to the shift to international sales.
Other.
## Table 1 ##
Revenues for this business segment, which includes the mini C-arm business, the digital general radiography business and the conventional general radiography service business, decreased primarily due to a $5.9 million decrease in digital general radiography systems sold worldwide, as a result of our phase out of that business, and a $1.1 million decrease in product sales of our mini C-arm products as discussed above.
The improvements in operating income were primarily due to lower operating expenses as a result of our decision to de-emphasize the digital general radiography systems business, which has been substantially phased out, and to reallocate resources and costs in order to focus on the more profitable and faster growing digital mammography systems.
Liquidity and Capital Resources At September 30, 2006 we had approximately $115.7 million of working capital.
At that date our cash and cash equivalents totaled $29.9 million.
Our cash and cash equivalents balance decreased $84.1 million during fiscal 2006 primarily due to the use of $27.6 million in cash for the acquisition of the mammography intellectual property of Fischer Imaging, cash for the acquisition of AEG and related fees and expenses of $21.9 million net of cash acquired, cash for the acquisition of R2 and related fees and expenses of $13.4 million net of cash acquired, cash to acquire Suros and related fees and expenses of $136.5 million net of cash acquired and for the purchase of property and equipment of $13 million.
These uses of cash were partially offset by cash provided by financing and operating activities and the sale of intellectual property for $6.5 million.
Our operating activities provided us with $31.1 million of cash, which included net income of $27.4 million for fiscal 2006 increased by non-cash charges for depreciation and amortization of an aggregate $16.1 million, and the acquired in-process research and development charge of $19.9 million related to the Fischer, AEG, R2 and Suros acquisitions, which were partially offset by the $27.9 million tax benefit related to the exercise of non-qualified stock options.
Cash used by operations due to changes in our current assets and liabilities included an increase in inventory of $23.0 million and accounts receivable of $9.5 million.
These uses of cash were partially offset by an increase in accrued expenses of $14.5 million, an increase in deferred revenue of $10.5 million, and an increase in accounts payable of $3.9 million.
The increase in inventory was to support the increased sales volume, especially for digital mammography and in support of our domestic distribution of a new line of a third party extremity MRI system as well as an increase in amounts related to our newly acquired businesses.
The increase in accounts receivable was primarily due to the increased revenues during fiscal 2006.
The increase in deferred revenue was primarily due to an increase in the number of deferred service contracts for our core business as well as an increase in amounts related to our newly acquired businesses.
The increase in accrued expenses and accounts payable was due to increased expenditures to support our growing inventory and expenses as well as increase in amounts related to our newly acquired businesses.
Table of Contents Contractual Obligations The following table summarizes our contractual obligations and commitments as of September 24, 2011:
## Table 2 ##
(1) Our Convertible Notes can first be put to us on December 13, 2013, and we have assumed for purpose of the above table that the remaining portion of the Original Notes will be paid off in fiscal 2014.
On November 18, 2010, we exchanged Exchange Notes in an aggregate principal amount of $450.0 million for Original Notes in the aggregate principal amount of $450.0 million.
The first put date on the Exchange Notes is December 15, 2016, and we have assumed for purposes of the above table that the Exchange Notes will be paid off in fiscal 2017.
(2) The financing leases represent two leases for an office building and a manufacturing facility, which were required to be recorded on our balance sheet under US GAAP.
See Note 12 to our consolidated financial statements contained in Item 15 of this Annual Report for more information.
(3) Amounts represent those recorded in accrued expenses and other long-term liabilities on our consolidated balance sheet.
See Contingent Earn-Out Payments for a more complete description of our contingent earn-out obligations.
(4) Purchase obligations primarily relate to inventory purchases, and to a lesser extent, other operating expense commitments.
(5) Pension obligations do not include our obligation under the DCP of $17.2 million, which is recorded as a current liability.
The DCP benefits are generally paid out at retirement or termination of employment.
(6) This represents a private equity investment commitment with a limited liability partnership.
The above table does not reflect our long-term liabilities associated with uncertain tax positions recorded under FIN 48 (codified primarily in ASC 740, Income Taxes) totaling $11.2 million.
Due to the complexity associated with tax uncertainties, we cannot reasonably make a reliable estimate of the period in which we expect to settle these non-current liabilities.
See Note 8 to our consolidated financial statements contained in Item 15 of this Annual Report for more information on our unrecognized tax benefits.
In addition, certain of our cost method equity investments give us the option to acquire the company in the future.
Since it is not possible to estimate when, or even if, we will exercise our option to acquire these companies, we have not included these future potential payments in the table above.
Future Liquidity Considerations We expect to continue to review and evaluate potential acquisitions of businesses, products or technologies, and strategic alliances that we believe will complement our current or future business.
Subject to the Risk Factors set forth in Part I, Item 1A of this Annual Report and the general disclaimers set forth in our Special Note Regarding Forward-Looking Statements at the outset of this Annual Report, we believe that cash flow from
Corporate Corporate expenses in 2016 benefited from the absence of transaction costs associated with the Norcraft acquisition ($15.1 million in 2015).
This benefit was offset by higher employee-related costs and lower defined benefit plan income.
## Table 3 ##
(a) Represents external costs directly related to the acquisition of Norcraft and primarily includes expenditures for banking, legal, accounting and other similar services.
In future periods the Company may record, in the Corporate segment, material expense or income associated with actuarial gains and losses arising from periodic remeasurement of our liabilities for defined benefit plans.
At a minimum the Company will remeasure its defined benefit plan liabilities in the fourth quarter of each year.
Remeasurements due to plan amendments and settlements may also occur in interim periods during the year.
Remeasurement of these liabilities attributable to updating our liability discount rates and expected return on assets may, in particular, result in material income or expense recognition.
Liquidity and Capital Resources Our primary liquidity needs are to support working capital requirements, fund capital expenditures and service indebtedness, as well as to finance acquisitions, repurchase shares of our common stock and pay dividends to stockholders, as deemed appropriate.
Our principal sources of liquidity are cash on hand, cash flows from operating activities, availability under our credit facility and debt issuances in the capital markets.
Our operating income is generated by our subsidiaries.
There are no restrictions on the ability of our subsidiaries to pay dividends or make other distributions to Fortune Brands.
In December 2017, our Board of Directors increased the quarterly cash dividend by 11% to $0.20 per share of our common stock.
Our Board of Directors will continue to evaluate dividend payment opportunities on a quarterly basis.
There can be no assurance as to when and if future dividends will be paid, and at what level, because the payment of dividends is dependent on our financial condition, results of operations, cash flows, capital requirements and other factors deemed relevant by our Board of Directors.
We periodically review our portfolio of brands and evaluate potential strategic transactions to increase shareholder value.
However, we cannot predict whether or when we may enter into acquisitions, joint ventures or dispositions, make any purchases of shares of our common stock under our share repurchase program, or pay dividends, or what impact any such transactions could have on our results of operations, cash flows or financial condition, whether as a result of the issuance of debt or equity securities, or otherwise.
Our cash flows from operations, borrowing availability and overall liquidity are subject to certain risks and uncertainties, including those described in the section “Item 1A.
Risk Factors.
” In June 2016, the Company amended and restated its credit agreement to combine and rollover the existing revolving credit facility and term loan into a new standalone $1.25 billion revolving credit facility.
This amendment and restatement of the credit agreement was a non-cash transaction for the Company.
Terms and conditions of the credit agreement, including the total commitment amount, essentially remained the same as under the 2011 credit agreement.
The revolving credit facility will mature in June 2021 and borrowings thereunder will be used for general corporate purposes.
On December 31, 2017 and December 31, 2016, our outstanding borrowings under these facilities were $615.0 million and $540.0 million, respectively.
At December 31, 2017 and December 31, 2016, the current portion of longterm debt was zero.
Interest rates under the facility are variable based on LIBOR at the time of the
MetLife, Inc.  Notes to the Consolidated Financial Statements — (Continued) Credit Risk on Freestanding Derivatives The Company may be exposed to credit-related losses in the event of nonperformance by counterparties to derivative financial instruments.
Generally, the current credit exposure of the Company’s derivative contracts is limited to the net positive estimated fair value of derivative contracts at the reporting date after taking into consideration the existence of netting agreements and any collateral received pursuant to credit support annexes.
The Company manages its credit risk related to OTC derivatives by entering into transactions with creditworthy counterparties, maintaining collateral arrangements and through the use of master agreements that provide for a single net payment to be made by one counterparty to another at each due date and upon termination.
Because exchange-traded futures and options are effected through regulated exchanges, and positions are marked to market on a daily basis, the Company has minimal exposure to credit-related losses in the event of nonperformance by counterparties to such derivative instruments.
See Note 5 for a description of the impact of credit risk on the valuation of derivative instruments.
The Company enters into various collateral arrangements which require both the pledging and accepting of collateral in connection with its OTC derivative instruments.
At December 31, 2011 and 2010, the Company was obligated to return cash collateral under its control of $9.5 billion and $2.6 billion, respectively.
This cash collateral is included in cash and cash equivalents or in short-term investments and the obligation to return it is included in payables for collateral under securities loaned and other transactions in the consolidated balance sheets.
At December 31, 2011 and 2010, the Company had received collateral consisting of various securities with a fair market value of $2.5 billion and $984 million, respectively, which were held in separate custodial accounts.
Subject to certain constraints, the Company is permitted by contract to sell or repledge this collateral, but at December 31, 2011, none of the collateral had been sold or repledged.
The Company’s collateral arrangements for its OTC derivatives generally require the counterparty in a net liability position, after considering the effect of netting agreements, to pledge collateral when the fair value of that counterparty’s derivatives reaches a pre-determined threshold.
Certain of these arrangements also include credit-contingent provisions that provide for a reduction of these thresholds (on a sliding scale that converges toward zero) in the event of downgrades in the credit ratings of the Company and/or the counterparty.
In addition, certain of the Company’s netting agreements for derivative instruments contain provisions that require the Company to maintain a specific investment grade credit rating from at least one of the major credit rating agencies.
If the Company’s credit ratings were to fall below that specific investment grade credit rating, it would be in violation of these provisions, and the counterparties to the derivative instruments could request immediate payment or demand immediate and ongoing full overnight collateralization on derivative instruments that are in a net liability position after considering the effect of netting agreements.
The following table presents the estimated fair value of the Company’s OTC derivatives that are in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged.
The table also presents the incremental collateral that the Company would be required to provide if there was a one notch downgrade in the Company’s credit rating at the reporting date or if the Company’s credit rating sustained a downgrade to a level that triggered full overnight collateralization or termination of the derivative position at the reporting date.

<table><tr><td>Net tangible assets acquired as of May 2, 2006</td><td>$23,700</td></tr><tr><td>In-process research and development</td><td>600</td></tr><tr><td>Developed technology and know how</td><td>1,900</td></tr><tr><td>Customer relationship</td><td>800</td></tr><tr><td>Trade name</td><td>400</td></tr><tr><td>Deferred income taxes</td><td>-3,000</td></tr><tr><td>Goodwill</td><td>6,900</td></tr><tr><td>Estimated Purchase Price</td><td>$31,300</td></tr></table>
<table><tr><td></td><td colspan="6"> Years Ended</td></tr><tr><td></td><td colspan="2">September 24, 2005</td><td colspan="2">September 25, 2004</td><td colspan="2"> Change</td></tr><tr><td></td><td> Amount</td><td>% of Total Segment Revenue</td><td> Amount</td><td>% of Total Segment Revenue</td><td>Amount</td><td> %</td></tr><tr><td>Total Revenues</td><td>$23,414</td><td>100%</td><td>$30,596</td><td>100%</td><td>-$7,182</td><td>-23%</td></tr><tr><td>Operating Income</td><td>$3,996</td><td>17%</td><td>$327</td><td>1%</td><td>$3,669</td><td>1,122%</td></tr></table>
<table><tr><td></td><td colspan="5"> Payments Due by Period</td></tr><tr><td> Contractual Obligations</td><td> Less than 1 year</td><td> 1-3 years</td><td> 3-5 years</td><td> More than 5 years</td><td> Total</td></tr><tr><td>Long-Term Debt Obligations -1</td><td>$—</td><td>$1,275,000</td><td>$—</td><td>$450,000</td><td>$1,725,000</td></tr><tr><td>Interest on Long-Term Debt Obligations</td><td>34,500</td><td>56,250</td><td>18,000</td><td>4,500</td><td>113,250</td></tr><tr><td>Operating Leases</td><td>19,793</td><td>31,703</td><td>19,863</td><td>33,461</td><td>104,820</td></tr><tr><td>Financing Leases -2</td><td>2,598</td><td>5,585</td><td>5,937</td><td>6,346</td><td>20,466</td></tr><tr><td>Accrued Contingent Consideration -3</td><td>100,255</td><td>48,872</td><td>—</td><td>—</td><td>149,127</td></tr><tr><td>Deferred payment to TCT</td><td>47,949</td><td>—</td><td>—</td><td>—</td><td>47,949</td></tr><tr><td>Purchase Obligations -4</td><td>27,678</td><td>6,205</td><td>144</td><td>—</td><td>34,027</td></tr><tr><td>Pension Obligations -5</td><td>349</td><td>760</td><td>835</td><td>6,120</td><td>8,064</td></tr><tr><td>Private Equity Investment -6</td><td>524</td><td>—</td><td>—</td><td>—</td><td>524</td></tr><tr><td>Total Contractual Obligations</td><td>$233,646</td><td>$1,424,375</td><td>$44,779</td><td>$500,427</td><td>$2,203,227</td></tr></table>
<table><tr><td><i>(In millions)</i></td><td>2016</td><td>2015</td></tr><tr><td>General and administrative expense</td><td>$-80.9</td><td>$-70.1</td></tr><tr><td>Defined benefit plan income</td><td>2.9</td><td>6.1</td></tr><tr><td>Defined benefit plan recognition of actuarial losses</td><td>-1.9</td><td>-2.5</td></tr><tr><td>Norcraft transaction costs<sup>(a)</sup></td><td>—</td><td>-15.1</td></tr><tr><td>Total Corporate expenses</td><td>$-79.9</td><td>$-81.6</td></tr></table>

Question: In the section with the most Interest on Long-Term Debt Obligations, what is the growth rate of Financing Leases -2?
Answer: 1.14973